/ Browse·page 697 of 1630

Browse EX-10 agreements

19,554 total material contract exhibits.

Filters

** **

INVESTMENT MANAGEMENT TRUST AGREEMENT

This Investment Management Trust Agreement (this “Agreement”) is made as of August 12, 2026 by and between Thunder Bridge Capital Partners V, Ltd., a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).

** **

WHEREAS, the Registration Statement on Form S-1 (File No. 333-296759), as amended (the “Registration Statement”), and prospectus for the Company’s initial public offering of 26,100,000 units (or 30,015,000 units in the aggregate if the underwriters’ option to purchase additional units (the “Over-Allotment Option”) is exercised in full), at a price of $10.00 per unit (the “Units”), each Unit consisting of one Class A ordinary share of the Company, par value $0.0001 per share (the “Ordinary Share(s)”), and one-third of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Ordinary Share at an exercise price of $11.50 per share, subject to adjustment (such initial public offering hereinafter referred to as the “Offering”), has been declared effective as of the date hereof by the U.S. Securities and Exchange Commission (capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Registration Statement); and

** **

…

Open document
EX-10.1·8-K·CIK 2140030·ACC 0001213900-26-090202·Filed Aug 14, 2026, 16:41 ET

Term Sheet

Scilex Holding Co

TERM SHEET
Strategic Investment into Scilex Holding Company

Date: 3 July 2026

1.

Parties

Investor
iHolding Group LLP
420 Tattimbet Street
Medeu District
Almaty
Republic of Kazakhstan

Company
Scilex Holding Company

2.

Transaction

The Investor agrees to invest the sum of US$100,000,000 into the Company through the acquisition of newly issued equity securities of the Company.

3.

Purchase Price

The investment shall be made at a price of US$15.00 per share. Based upon the investment amount, the Investor shall receive approximately 6,666,667 shares.

4.

Security

The securities issued pursuant to this investment shall consist of newly issued common shares of the Company, unless otherwise mutually agreed in writing between the parties.

5.

Purpose of Investment

−

Expansion of healthcare and medical technology initiatives;

−

Product development and commercialization;

−

Acquisitions and strategic partnerships;

−

Working capital and operational growth;

−

Intellectual property expansion;

−

General corporate purposes.

6.

Scilex Products and Pipeline

Existing Commercial Products:

1.

ZTlido® (1.8% lidocaine topical system equivalent to 5% lidocaine) for the treatment of Postherpetic Neuralgia-PHN related pain.

2.

ELYXYBTM (celecoxib) oral solution for acute treatment of migraine

3.

GLOPERBA®(colchicine USP) oral solution for the prevention of painful gout flares in adults

Development Stage Products / Technologies:

1.

SP-103 is the Next-Generation, 5.4% Lidocaine Topical System


Exhibit 10.4

4.

…

Open document
EX-10.4·10-Q·CIK 1820190·ACC 0001193125-26-352464·Filed Aug 14, 2026, 16:41 ET

Bindingtermsheet

Scilex Holding Co

BINDINGTERMSHEET

DATAVAULTAIINC.–SCILEXHOLDINGCOMPANY

Dated:June24,2026

This binding term sheet (this “Term Sheet”) sets forth the principal terms upon which Scilex Holding Company, a Delaware corporation (“Scilex”), proposes to make cash or Scilex’s common stock or its subsidiaries’ publicly traded securities contributiontoDatavaultAIInc.,aDelawarecorporation(“Datavault”and,togetherwithScilex, the “Parties” and each, a “Party”), in exchange for the Bitcoins (BTC) currently held in Datavault’s Biconomy digital wallet (the “Wallet”), on the terms and subject to the conditions set forth below (the “Transaction”).

| | |

…

Open document
EX-10.3·10-Q·CIK 1820190·ACC 0001193125-26-352464·Filed Aug 14, 2026, 16:41 ET

Binding Term Sheet

Scilex Holding Co

BINDING TERM SHEET
DATAVAULT AI INC. – SCILEX HOLDING COMPANY

Dated: April 26, 2026

This binding term sheet (this “Term Sheet”) sets forth the principal terms upon which Scilex Holding Company, a Delaware corporation (“Scilex”), proposes to make an upfront cash contribution to Datavault AI Inc., a Delaware corporation (“Datavault” and, together with Scilex, the “Parties” and each, a “Party”), in exchange for the right to receive certain payments tied to revenues generated by Datavault’s quantum-ready edge network, on the terms and subject to the conditions set forth below (the “Transaction”).

| | |

…

Open document
EX-10.1·10-Q·CIK 1820190·ACC 0001193125-26-352464·Filed Aug 14, 2026, 16:41 ET

ADAMS STREET CREDIT SOLUTIONS FUND

DISTRIBUTION AND SERVICING PLAN ADOPTED PURSUANT TO RULE 12b-1

WHEREAS, Adams Street Credit Solutions Fund (the ”Company”) is a closed-end management investment company that intends to file an election to be regulated as a business development company under the Investment Company Act of 1940, as amended (the ”1940 Act”);

WHEREAS, the Company intends to apply to the Securities and Exchange Commission (the “SEC”) for an exemptive order that would permit the Company to offer multiple classes of common shares of beneficial interest of the Company (the “Shares”) with, among other things, asset-based distribution and/or service fees (the “Order”);

WHEREAS, if granted, reliance on the Order would require the Company to comply with the provisions of Rule 12b-1 under the 1940 Act as if it were an open-end management investment company;

WHEREAS, the Company intends to employ Foreside Fund Services, LLC (“Foreside”) as distributor of the Shares of each Class (as defined below) of the Company; and

WHEREAS, in anticipation of receipt of the Order, the Company seeks to adopt voluntarily a distribution and servicing plan pursuant to Rule 12b-1 under the 1940 Act (the “Plan”), with respect to the classes of Shares set forth on Exhibit A hereto, as such Exhibit may be amended from time to time (each, a “Class”).

…

Open document
EX-10.3·10-Q·CIK 1772918·ACC 0001193125-26-352459·Filed Aug 14, 2026, 16:40 ET

Amended and Restated Multiple Class Plan

ADAMS STREET CREDIT SOLUTIONS FUND

ADAMS STREET CREDIT SOLUTIONS FUND

AMENDED AND RESTATED MULTIPLE CLASS PLAN

ADOPTED PURSUANT TO RULE 18F-3

June 2, 2026

WHEREAS, Adams Street Credit Solutions Fund (the “Company”) is a closed-end management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended (the “1940 Act”); and

WHEREAS, the Company is permitted to rely on an exemptive order from the Securities and Exchange Commission (the “SEC”) to offer multiple classes of shares (the “Order”); and

WHEREAS, pursuant to the Order, the Company must comply with the provisions of Rule 18f-3 under the 1940 Act as if it were an open-end management investment company; and

WHEREAS, Rule 18f-3 requires that a board of trustees of an investment company desiring to offer multiple classes of shares pursuant to said Rule adopt a plan setting forth the differences among the classes with respect to shareholder services, distribution arrangements, expense allocations and any related conversion features or exchange privileges; and

WHEREAS, the Board of Trustees of the Company (the “Board”) voluntarily adopted a plan pursuant to Rule 18f-3 on August 19, 2025 (the “Initial Plan”), so that the Company may issue multiple classes of common shares of beneficial interest (“Shares”) in compliance with the Order.

NOW, THEREFORE, the Company hereby seeks to amend and restate that Initial Plan (as amended and restated, the “Plan”) on the following terms and conditions:

…

Open document
EX-10.2·10-Q·CIK 1772918·ACC 0001193125-26-352459·Filed Aug 14, 2026, 16:40 ET

Promissory Note

BRAINSTORM CELL THERAPEUTICS INC.

​

Exhibit 10.9

THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT.

THE ISSUE PRICE OF THIS NOTE IS $151,800.00

THE ORIGINAL ISSUE DISCOUNT IS $19,800.00

Principal Amount: $151,800.00 Issue Date: May 5, 2026
Purchase Price: $132,000.00 ​

​

PROMISSORY NOTE

…

Open document
EX-10.9·10-Q·CIK 1137883·ACC 0001104659-26-097275·Filed Aug 14, 2026, 16:38 ET

Promissory Note

BRAINSTORM CELL THERAPEUTICS INC.

THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT.

THE ISSUE PRICE OF THIS NOTE IS $151,800.00

THE ORIGINAL ISSUE DISCOUNT IS $19,800.00

Principal Amount: $151,800.00 Issue Date: July 6, 2026
Purchase Price: $132,000.00 ​

​

PROMISSORY NOTE

…

Open document
EX-10.6·10-Q·CIK 1137883·ACC 0001104659-26-097275·Filed Aug 14, 2026, 16:38 ET

Promissory Note

BRAINSTORM CELL THERAPEUTICS INC.

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH MAY BE THE LEGAL COUNSEL OPINION (AS DEFINED IN THE PURCHASE AGREEMENT)), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144, RULE 144A OR REGULATION S UNDER SAID ACT OR OTHER APPLICABLE EXEMPTION. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

​ ​
Principal Amount: $115,000.00 Issue Date: July 2, 2026
Actual Amount of Purchase Price: $100,000.00 ​

​

PROMISSORY NOTE

…

Open document
EX-10.5·10-Q·CIK 1137883·ACC 0001104659-26-097275·Filed Aug 14, 2026, 16:38 ET

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

** **

AMENDED AND RESTATED PROMISSORY NOTE

Principal Amount: $20,000.00 Dated as of August 11, 2026

This Amended and Restated Promissory Note (this “Note”) amends and restates in its entirety that certain Promissory Note, dated as of June 23, 2026 (the “Original Note”), made by Lionheart Holdings, a Cayman Islands exempted company and blank check company (the “Maker”) in favor of The Ivy Companies, Inc., a Florida corporation, or its assigns or successors in interest (the “Payee”), in the original principal amount of Twenty Thousand Dollars ($20,000.00).

The Maker promises to pay to the order of the Payee the principal sum of Twenty Thousand Dollars ($20,000.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

| |

Open document
EX-10.6·10-Q·CIK 2015955·ACC 0001213900-26-090191·Filed Aug 14, 2026, 16:36 ET

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

** **

AMENDED AND RESTATED PROMISSORY NOTE

Principal Amount: $180,000.00 Dated as of August 11, 2026

This Amended and Restated Promissory Note (this “Note”) amends and restates in its entirety that certain Promissory Note, dated as of June 23, 2026 (the “Original Note”), made by Lionheart Holdings, a Cayman Islands exempted company and blank check company (the “Maker”), in favor of Lionheart Management, LLC, a Florida limited liability company, or its assigns or successors in interest (the “Payee”), in the original principal amount of One Hundred Eighty Thousand Dollars ($180,000.00).

…

Open document
EX-10.5·10-Q·CIK 2015955·ACC 0001213900-26-090191·Filed Aug 14, 2026, 16:36 ET

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

P R O M I S S O R Y N O T E

Principal Amount: $20,000.00 Dated as of June 23, 2026

Lionheart Holdings, a Cayman Islands exempted company and blank check company (the “Maker”) promises to pay to the order of The Ivy Companies, Inc., a Florida corporation, or its assigns or successors in interest (the “Payee”) the principal sum of Twenty Thousand Dollars ($20,000.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

…

Open document
EX-10.4·10-Q·CIK 2015955·ACC 0001213900-26-090191·Filed Aug 14, 2026, 16:36 ET